The study by Legrand et al. (2013) provides valuable insights into the management and outcomes of FIP1L1::PDGFRA-associated chronic eosinophilic leukemia (F/P+ CEL), especially regarding the efficacy and dosing strategies of imatinib, a targeted therapy that has revolutionized treatment for this condition [94]. This evidence concerns the gene PDGFRA and Chronic Eosinophilic Leukemia, Not Otherwise Specified.